A study of 3,500 women at high risk of developing ovarian/fallopian cancer were screened annually for approximately three years with the CA-125 blood test and transvaginal ultrasound. In this population, women in the Phase I study were diagnosed with early stage disease more than the national average.
The study also suggested that genotype, rather than family history, was key to risk.
Read the abstract here
Read the accompanying editorial here